000186022 000__ 01532fam\a2200337\a\4500
000186022 001__ 186022
000186022 005__ 20220217103703.0
000186022 008__ 961101s1996\\\\dcu\\\\\\\\\\f000\0\eng\d
000186022 020__ $$a0160534666
000186022 035__ $$a(OCoLC)ocm35834611
000186022 035__ $$9(IS)TVY7115
000186022 035__ $$9AAV4808SI
000186022 035__ $$a186022
000186022 040__ $$aGPO$$cGPO
000186022 043__ $$an-us---
000186022 049__ $$aISUW
000186022 074__ $$a1019-A-01
000186022 0860_ $$aY 4.C 73/8:104-93
000186022 088__ $$aSerial no. 104-93 (United States. Congress. House. Committee on   Commerce)
000186022 1101_ $$aUnited States.$$bCongress.$$bHouse.$$bCommittee on Commerce.$$bSubcommittee on Oversight and Investigations.
000186022 24510 $$aFDA integrity issues :$$bhearing before the Subcommittee on        Oversight and Investigations of the Committee on Commerce, House of             Representatives, One Hundred Fourth Congress, second session, on Visx Inc.      document disclosure, July 31, 1996.
000186022 260__ $$aWashington :$$bU.S. G.P.O. :$$bFor sale by the U.S. G.P.O., Supt. of Docs., Congressional Sales Office,$$c1996.
000186022 300__ $$aiii, 83 p. ;$$c24 cm.
000186022 500__ $$aDistributed to some depository libraries in microfiche.
000186022 500__ $$aShipping list no.: 96-0375-P.
000186022 500__ $$a"Serial no. 104-93."
000186022 61010 $$aUnited States.$$bFood and Drug Administration$$xManagement.
000186022 61010 $$aUnited States.$$bFood and Drug Administration$$xOfficials and   employees.
000186022 650_0 $$aMedical instruments and apparatus$$xMarketing$$xCertification$$zUnited States.
000186022 650_0 $$aFraud investigation$$zUnited States.
000186022 85230 $$bdfich$$hY 4.C 73/8:$$i104-93
000186022 909CO $$ooai:library.usi.edu:186022$$pGLOBAL_SET
000186022 948__ $$ac:jb
000186022 980__ $$aBIB
000186022 980__ $$aGOV RESOURCE